INFeD® (iron dextran)

Effective Date: 10/23/12
Date Developed: 10/15/12 by Albert Reeves MD
Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20,
2/2/21, 8/3/21, 2/1/22, 1/31/23

INFeD® is a Hematinic. The released iron, from the plasma, eventually replenishes the
depleted iron stores in the bone marrow where it is incorporated into hemoglobin

Pre-Authorization Criteria:

Iron deficiency in adult and pediatric patients ≥4 months of age with intolerance to oral
iron or unsatisfactory response to oral iron after trying at least two different forms (e.g.
sulfate, gluconate, fumarate, carbonate)

NOTE: There are various forms of iron for parenteral use, each with individual dosing
regimens. The VCHCP formulary is restricted to Infed, Injectafer, Ferrlecit and Ferheme.

NOTE: The Institute for Safe Medication Practices (ISMP) includes this medication among
its list of drugs which have a heightened risk of causing significant patient harm when
used in error.

Dosing: Adult

NOTE: Maximum cumulative dose is restricted to 1000 mg per 30 days

Iron-deficiency anemia: I.M. (INFeD®), I.V., INFeD®):

Dose (mL) = 0.0442 (desired Hgb - observed Hgb) x LBW + (0.26 x LBW) Desired
hemoglobin: Usually 14.8 g/dL

LBW = Lean body weight in kg
Iron replacement therapy for blood loss: (INFeD®), I.V. (INFeD®):
Replacement iron (mg) = blood loss (mL) x Hct

Maximum daily dosage: Daily dosages should be limited to 100 mg iron (2 mL)

Total dose infusion (unlabeled): The entire dose (estimated iron deficit) may be diluted and administered as a one-time I.V. infusion.

Cancer-/chemotherapy-associated anemia I.V.: Test dose: 25 mg slow I.V. slow push, followed 1 hour later by 100 mg over 5 minutes; larger doses up to total dose infusion (over several hours) may be administered. Low-molecular-weight iron dextran preferred.

Dosing: Pediatric
Iron-deficiency anemia: I.M. (INFeD®), I.V. INFeD®):

Children 5-15 kg: Should not normally be given in the first 4 months of life: Dose

(mL) = 0.0442 (desired Hgb - observed Hgb) x W + (0.26 x W)

Desired hemoglobin: Usually 12 g/dL W =

Total body weight in kg

Children >15 kg: Refer to adult dosing.

Iron replacement therapy for blood loss: Refer to adult dosing.

Maximum daily dose:

Children <5 kg: 25 mg iron (0.5 mL)

Children 5-10 kg: 50 mg iron (1 mL)

≥10 kg: Refer to adult dosing.
**DOSAGE FORMS AND STRENGTHS**

Injection, solution:

INFeD®: Elemental iron 50 mg/mL (2 mL) [low-molecular-weight iron dextran]

**PRECAUTIONS**

**I.M.** (INFeD®): Use Z-track technique (displacement of the skin laterally prior to injection); injection should be deep into the upper outer quadrant of buttock; alternate buttocks with subsequent injections. Administer test dose at same recommended site using the same technique.

**I.V.** Test dose should be given gradually over at least 30 seconds (INFeD®).

Subsequent dose(s) may be administered by I.V. bolus undiluted at a rate not to exceed 50 mg/minute or diluted in 250-1000 mL NS and infused over 1-6 hours (initial 25 mL should be given slowly and patient should be observed for allergic reactions); avoid dilutions with dextrose (increased incidence of local pain and phlebitis).

- **Delayed reaction:** Delayed (1-2 days) infusion reaction (including arthralgia, back pain, chills, dizziness, and fever) may occur with large doses (eg, total dose infusion) of I.V. iron dextran; usually subsides within 3-4 days. May also occur (less commonly) with I.M. administration; subsiding within 3-7 days.

- **Hypersensitivity/anaphylactoid reactions:**

- **[U.S. Boxed Warning]:**

  Deaths associated with parenteral administration following anaphylactic-type reactions have been reported (use only where resuscitation equipment and personnel are available). A test dose should be administered to all patients prior to the first therapeutic dose. Anaphylactic and other hypersensitivity reactions have occurred.
even in patients who tolerated the test dose. A history of drug allergy (including multiple drug allergies) and/or the concomitant use of an ACE inhibitor may increase the risk of anaphylactic-type reactions.

REFERENCES


9. INFeD (iron dextran complex) [prescribing information]. Madison, NJ: Allergan USA Inc; April 2021.


---

**Revision Date** | **Content Revised (Yes/No)** | **Contributors** | **Review/Revision Notes**
---|---|---|---
1/24/17 | No | Catherine Sanders, MD; Robert Sterling, MD | Annual review
1/23/18 | No | Catherine Sanders, MD; Robert Sterling, MD | Annual review
<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Authors</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/22/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>2/18/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>2/2/21</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>8/3/21</td>
<td>Yes</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Additions and deletions; added references</td>
</tr>
<tr>
<td>2/1/22</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/31/23</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>